Organoids in Drug Discovery
Predictive methods are needed to increase the chance of success in your drug programs before clinical trials. Organoids are a beneficial tool in drug discovery and toxicity testing, aiding target discovery, validation, and pre-clinical testing. Organoid models provide a more physiologically relevant cellular composition and tissue structure than standard 2D models, with increased accuracy and higher throughput. Additionally, patient-derived organoids can be used to predict drug toxicity and efficacy, allowing you to make precise and confident decisions to advance your drug candidates.
Learn how organoids can help your drug-discovery workflow below.
Interview: The Role of Organoids and Organ-On-A-Chip Systems in Drug Discovery
Drs Bas Trietsch, Chief Technology Officer at MIMETAS, and Jenna Moccia, Director of Product Management at ƽ Technologies, discuss the challenges that lead pharma companies to adopt advanced in vitro models, such as organoids and organ-on-a-chip, and the benefits they see after incorporating these systems in their research.
Watch Now >-
Nature Research Round Table: The Promise of Organoid MedicineDr. Takanori Takebe discusses how organoids can be used to expand clinical applications of diseases and disorders. Dr. Takebe is an Assistant Professor at the Cincinnati Children’s Hospital Medical Center and Associate Professor at Yokohama City University. <br><br> This presentation was part of a Round Table series titled “Advances in Organoid Applications”, organized in partnership with Nature Research and held at the Springer Nature headquarters in London, UK in June 2019. There, global organoid experts gathered to discuss the current state of the technology. Core discussions centered around protocol standardization, translation into patient care, nomenclature, and understanding what questions a given organoid culture can and can’t answer. -
Nature Research Round Table: Organoids as an Enabling Technology for Precision Cancer MedicineDr. Mathew Garnett describes his work banking tumor organoids to create new disease models for cancer that more accurately reflect the disease. Dr. Garnett is a Group Leader at the Wellcome Sanger Institute <br><br> This presentation was part of a Round Table series titled “Advances in Organoid Applications”, organized in partnership with Nature Research and held at the Springer Nature headquarters in London, UK in June 2019. There, global organoid experts gathered to discuss the current state of the technology. Core discussions centered around protocol standardization, translation into patient care, nomenclature, and understanding what questions a given organoid culture can and can’t answer. -
ISSCR Innovation Showcase: Applications of Organoid and Organotypic Cultures in Infectious Diseases, Nephrotoxicity, and Highly Relevant Cell-Based AssayIn this Innovation Showcase talk from ISSCR 2020 Virtual, Drs. Juan Hou, Martin Stahl, and Philipp Kramer show how organoids can be used to study infectious diseases, nephrotoxicity, and cell-based assay development. -
Single-Cell Characterization of Dorsal and Ventral Forebrain Organoid ModelsSTEMdiff™ Dorsal and Ventral Forebrain Organoid Differentiation Kits can be used to generate models of the developing human forebrain. In this Innovation Showcase from ISSCR 2021, Leon Chew presents data on the cell type composition and activity of the resulting organoids, including gene expression using single-cell sequencing and microelectrode array recording.
